Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Henlius Releases Positive Results for PD-1 as First-Line Therapy for SCLC

publication date: Jun 6, 2022

Shanghai Henlius Biotech reported its anti-PD-1 improved median overall survival to 15.4 months from 10.9 months as a first-line treatment for extensive-stage small-cell lung cancer. Hansizhuang (serplulimab) was administered together with chemotherapy and compared to chemotherapy alone. In March 2022, the PD-1 was approved in China to treat MSI-H solid tumors. Henlius said it has filed two additional NDAs in China for the drug, and it is conducting nine other serplulimab clinical trials around the world. Henlius released the data at the ASCO conference. More details....

Stock Symbols: (HK: 2696)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China